Author

SubbaReddy Gunneri

Observed names: Gunneri, SubbaReddy, Subba Reddy Gunneri, Subbareddy Gunneri

Observed institution: Biological E (India)

OpenAlex ID: A5031967456

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

2022 · Subhash Thuluva, Vikram Paradkar, et al. · EBioMedicine · 75

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

2023 · Subhash Thuluva, Vikram Paradkar, et al. · Human Vaccines & Immunotherapeutics · 39

PDF

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

2022 · Subhash Thuluva, Vikram Paradkar, et al. · Vaccine · 31

PDF

Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6–8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study

2024 · Ramesh V. Matur, Subhash Thuluva, et al. · Vaccine · 11

PDF

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants

2023 · Subhash Thuluva, SubbaReddy Gunneri, et al. · Contemporary Clinical Trials Communications · 5

Immunogenicity and safety of Biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial

2026 · Subhash Thuluva, Ramesh V. Matur, et al. · The Lancet Regional Health - Southeast Asia · 4

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5–80 years in India: a phase 3, single-blind, randomised controlled trial

2025 · Subhash Thuluva, Vikram Paradkar, et al. · The Lancet Regional Health - Southeast Asia · 4

Immunogenicity and safety of a multi-human dose formulation of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6–8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

2025 · Subhash Thuluva, Ramesh V. Matur, et al. · Frontiers in Immunology · 4

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A prospective double-blind randomized phase III clinical study

2025 · Subhash Thuluva, Vikram Paradkar, et al. · IJID Regions · 2

Safety and immunogenicity of Biological E's typhoid conjugate vaccine TYPHIBEVⓇ concomitantly administered with measles rubella vaccine: a phase IV prospective, multicenter study

2025 · Subhash Thuluva, Ramesh V Matur, et al. · IJID Regions · 2

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit COVID19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

2022 · Subhash Thuluva, Vikram Paradkar, et al. · SSRN Electronic Journal · 2

Safety and immunogenicity of a 14-valent pneumococcal conjugate vaccine (BE-PCV14) administered in a 3p + 1 schedule to healthy Indian infants and toddlers: a prospective, multicenter, active-controlled phase IV trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · BMC Infectious Diseases · 1

Association Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM197-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Vaccines

Safety, Immunogenicity of Co-Administered Vaccines, and Lot-to-Lot Consistency of a 14-Valent Pneumococcal Conjugate Vaccine (PNEUBEVAX 14®) Administered at 6–10–14 Weeks in Healthy Infants: A Multicenter, Phase IV Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Vaccines

PDF

Immunogenicity and Safety of Biological E’s Monovalent rDNA Hepatitis B Vaccine (BEVAC®) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial

2026 · Subhash Thuluva, Subbareddy Gunneri, et al. · Viruses

PDF

Corrigendum to ‘Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study’ [IJID Regions, volume 17 (2025) 100786]

2026 · Subhash Thuluva, Vikram Paradkar, et al. · IJID Regions

Immunogenicity and Safety of Biological E’s 14-valent Pneumococcal Conjugate Vaccine Pneubevax 14® in a 2+1 Infant Schedule: Multicenter, Randomized, Active-controlled, Single-blind Phase Iii Trial

2026 · Thuluva, Subhash, Matur, Ramesh, et al.

Coadministration of Biological E’s 14 Valent Pneumococcal Conjugate Vaccine Pneubevax 14® With Routine Epi Vaccines in Infants: Evidence of Immunogenic Non Interference

2026 · Thuluva, Subhash, Subbareddy Gunneri, et al.

Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply

2025 · Subhash Thuluva, Vikram Paradkar, et al. · The Lancet Regional Health - Southeast Asia

A multi-centre, single arm, Phase 3 study to assess the safety and reactogenicity of biological Es Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine in ≥6 months old infants to ≤45 years old adults.

2025 · Subhash Thuluva, Ramesh V. Matur, et al. · Vaccine X

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

2023 · Thuluva, Subhash, Paradkar, Vikram, et al. · Figshare

Selection of Optimum Formulation of RBD-Based Protein Sub-Unit Covid19 Vaccine (Corbevax) Based on Safety and Immunogenicity in an Open-Label, Randomized Phase-1 and 2 Clinical Studies

2022 · Subhash Thuluva, Vikram Paradkar, et al. · SSRN Electronic Journal

Works count: 22

Citation count: 180

H-index: 5

I10-index: 4